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Acute aortic dissection (AAD) is a life-threating disease; however, there is almost no effective pharma-
cotherapy for it. An increase in c-Jun N-terminal kinase (JNK) phosphorylation and smooth muscle cell
(SMC) apoptosis is observed tissues in patients with AAD. Therefore, we hypothesized that an acute rise
in blood pressure leads to SMC death through phosphorylation of JNK or p38, which may cause AAD. We
investigated the inﬂuence of cyclic mechanical stretch, which mimics an acute increase in blood pres-
sure, on cultured rat aortic SMCs (RASMCs) and examined the changes in JNK and p38 phosphorylation.
Further, we investigated the effect of olmesartan, an angiotensin II receptor blocker, on stretch-induced
RASMC death. We found that mechanical stretch-induced RASMC death in a time-dependent manner,
which correlated with the phosphorylation of JNK and p38. Olmesartan inhibited RASMC death and the
phosphorylation of JNK and p38. JNK and p38 inhibitors reversed stretch-induced RASMC death. These
results suggest that acute mechanical stretch causes JNK and p38 phosphorylation, which may result in
SMC death leading to aortic dissection. Olmesartan may be used for pharmacotherapy to prevent aortic
dissection, independent of its blood pressure-lowering effect, through its inhibition of JNK and p38
phosphorylation.
© 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute aortic dissection (AAD) is a disease associated with high
morbidity and mortality (1e3). AAD begins with a sudden initial
tear in the aortic media, and this tear allows pulsatile blood to enter
the media and cause separation of the medial layer along the
effective length of the vessel (4e6). However, the molecular
mechanisms by which the tear occurs are poorly understood (1,7).
Hypertension is present in 75% of individuals with aortic dissection,
and is known as a primary risk factor for cardiovascular disease
(1,2). Thus, it may be also related to the onset of AAD (8). When
surgical treatment is inapplicable, there is no effective treatment
for AAD other than the reduction of blood pressure (9). Therefore,
the development of nonsurgical pharmacotherapy for AAD is
required.hizumi).
acological Society.
. Production and hosting by ElseMitogen-activated protein (MAP) kinases, including extracel-
lular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase
(JNK), and p38, are a family of serine-threonine protein kinases that
are activated in response to a variety of extracellular stimuli (10).
ERK1/2 mediates cell proliferation and differentiation, which is
activated by various cell growth factors. On the other hand, JNK and
p38 are associated with stress responses, cell apoptosis, and growth
suppression, which are activated by stress or cytokines (11). It was
reported that AAD tissue showed a high level of phosphorylated
JNK, and that apoptosis occurred in the medial smooth muscle cell
(SMC) layers (12,13). In addition, phosphorylation of p38 was
induced by stretch stimuli in SMCs (12). These ﬁndings led us to
assume that apoptosis of SMCs in AAD tissue may be related to JNK
and p38 phosphorylation.
Angiotensin II has been shown to induce cellular hypertrophy in
vascular SMCs by acting through the G protein-coupled AT1 re-
ceptor, which results in various cardiovascular diseases and acti-
vates ERK1/2, JNK, and p38 (14e16). In recent years, much focus has
been placed on the role of G protein-coupled receptors, includingvier B.V. This is an open access article under the CC BY-NC-ND license (http://
S. Ito et al. / Journal of Pharmacological Sciences 127 (2015) 69e7470the angiotensin II receptor, because they can be activated without
agonist stimulation (17). The angiotensin II receptor also causes
initiation of an intra-cellular signaling cascade in response to me-
chanical stretch without agonist stimulation. A speciﬁc type of
angiotensin II receptor blocker (ARB) inhibits both agonist-induced
and stretch-induced activation (17). Olmesartan is known as a
potent ARB and works as an inverse agonist (4,18). We previously
reported that olmesartan inhibits SMC migration through the in-
hibition of JNK activation (19). Therefore, we hypothesized that
olmesartan may inhibit stretch-induced SMC death through the
inhibition of the JNK- or p38-mediated intracellular signaling
cascades.
In this study, we investigated cultured rat aortic smooth muscle
cell (RASMC) death induced by cyclic mechanical stretch, which
mimics an acute increase in blood pressure, and examined the ef-
fect of olmesartan on this event. We also investigated the changes
in stretch-induced intracellular signaling including JNK and p38
and examined the effect of olmesartan on these changes.
2. Materials and methods
The study design was approved by the animal care and use
committee of Nara Medical University based on the Guidelines for
the Use of Laboratory Animals of Nara Medical University (No.
11011) and this study was conducted in accordance with the Guide
for the Care and Use of Laboratory Animals as adopted and
promulgated by the United States National Institutes of Health.
2.1. Cell culture and mechanical stretch
RASMCswere isolated frommale Sprague-Dawley rats weighing
250e300 g according to previously published methods (20). The
cells were grown in Dulbecco's modiﬁed Eagle's medium (DMEM)
supplemented with 10% fetal bovine serum (FBS, HyClone, Logan,
UT) and antibiotics (100 units/ml penicillin, 100 mg/ml strepto-
mycin). The culture was maintained in a humidiﬁed atmosphere
containing 5% CO2 at 37 C. RASMCs from passage three to eight
were grown to 70%e80% conﬂuence in collagen I-coated (70 mg/
cm2) silicon chambers (STREX Inc., Osaka, Japan) and then growth-
arrested by incubation in serum-free DMEM for 24 h prior to use.
The cells were then subjected to mechanical stretch (60 cycles/min,
20% elongation) for a given time period by using the computer-
controlled mechanical Strain Unit (STREX Inc, Osaka, Japan) ac-
cording to previously published methods (21). After cyclic stretch,
the medium was replaced with DMEM-containing 0.1% FBS. For
western blot analysis, a portion of the RASMCs was lysed imme-
diately after stretch stimulation and lysate proteins were collected
in the manner described earlier (16). Immunoreactive bands were
visualized using the enhanced chemiluminescence (ECL) plus or
ECL prime systems and were quantiﬁed using densitometry. In
addition, a portion of the RASMCs were further incubated for 24 h
to detect cell viability using a 3-[4, 5-dimethylthiazol-2-phenyl]-2,
5-diphenyl-tetrazolium bromide (MTT) assay and cell death ac-
cording to the release of lactate dehydrogenase (LDH) into the
medium. In some studies, RASMCs were pre-incubated with
olmesartan, a JNK inhibitor (SP600125), and a p38 inhibitor
(SB203580) for 10 min, 20 min, and 4 h, respectively, before stim-
ulation with cyclic mechanical stretch. Band intensities were
quantiﬁed using the densitometry of the immunoblot with NIH
Image J software.
2.2. Materials
Olmesartan (RNH-6270) was kindly provided by Daiichi-Sankyo
Co., Ltd. (Tokyo). All other materials were purchased from Wako(Kyoto) or Nakalai Tesque (Kyoto) unless stated otherwise. The
antibodies used for western blot analysis, anti-pan- or phospho-
SAPK/JNK (Thr183/Tyr185) antibody and anti-pan- or phospho-
p38 MAP kinase (Thr180/Tyr182) antibody, were purchased from
Cell Signaling Technology. The ECL plus and ECL prime systems
were purchased fromGEHealthcare. Collagen I was purchased from
Nippon Meat Packers, Inc. (Osaka). All chemical compounds were
dissolved in dimethyl sulfoxide (DMSO) to a ﬁnal concentration of
less than 1%, except where speciﬁcally noted.
2.3. Statistical analyses
Data are reported as the mean ± standard deviation (S.D.). We
used a Student's t-test with Fisher's post-hoc test for intergroup
comparison. A P-value of <0.05 was considered to indicate statis-
tical signiﬁcance.
3. Results
3.1. Cyclic mechanical stretch-induced RASMC death evaluated
using MTT reduction and LDH release
The effect of cyclic mechanical stretch on RASMC death was
examined by measuring the MTT reduction and LDH release from
the cells. Fig. 1A and B show the viability and death rate of RASMCs
subject to cyclic mechanical stretch by 20% elongation for 0e4 h,
respectively. It was observed that the cell viability was decreased by
stretch in a time-dependent manner and 35% of cells were dead at
4 h, evaluated based on the MTT reduction (Fig. 1A). In accordance
with these results, the LDH release from RASMCs was increased by
stretch in a time-dependent manner up to 4 h (Fig. 1B). These re-
sults suggest that cyclic mechanical stretch-induced death in the
RASMCs.
3.2. Olmesartan inhibits cyclic mechanical stretch-induced cell
death in RASMCs
Next, we examined the effect of olmesartan on cyclic mechan-
ical stretch-induced death in RASMCs. As shown in Fig. 2, it was
obvious that cell viability was signiﬁcantly recovered with olme-
sartan treatment in a concentration-dependent manner.
3.3. Cyclic mechanical stretch causes activation of JNK and p38 in
RASMCs
The effects of cyclic mechanical stretch on the activation of JNK
and p38 were assessed using western blot analysis with phospho-
speciﬁc antibodies. RASMCs were exposed to cyclic mechanical
stretch with a 20% elongation for different periods of time and the
phosphorylation of JNK and p38 was measured. As shown in Fig. 3A
and B, both JNK and p38 were activated by cyclic mechanical
stretch. For both JNK and p38, the extent of activation increased
with the increase in stretch time, reached a peak at 5e30 min, and
then decreased to basal level at 60 min.
3.4. Olmesartan inhibits cyclic mechanical stretch-induced JNK and
p38 activation in RASMCs
To investigate whether stretch-induced JNK and p38 activation
are inﬂuenced by olmesartan treatment, we examined the effect of
olmesartan on cyclic mechanical stretch-induced activation of JNK
and p38 in RASMCs. As shown in Fig. 4A and B, it was found that
stretch-induced JNK and p38 activation were signiﬁcantly attenu-
ated by olmesartan in a dose-dependent manner.
Fig. 2. Inhibitory effect of olmesartan at different concentrations on stretch-induced
cell death in rat aortic smooth muscle cells (RASMCs). Olmesartan is abbreviated as
Olm. Colorimetric analysis of each value was normalized by arbitrarily setting the
colorimetric value of the control cells without stretch to 100% (*P < 0.05).
Fig. 3. Time courses for the effects of cyclic mechanical stretch (20% elongation) on the
activation of c-Jun N-terminal kinase (JNK) (A) and p38 (B) in rat aortic smooth muscle
cells (RASMCs). Densitometric analysis of each value was normalized by arbitrarily
setting the densitometric value of the control cells without stretch to 1. Each value
represent the mean ± S.D. (n ¼ 3). (*P < 0.05 compared with control without stretch).
Fig. 1. Time course for the effects of cyclic mechanical stretch (20% elongation) on cell
viability (A) (evaluated by 3-[4, 5-dimethylthiazol-2-phenyl]-2, 5-diphenyl-tetrazo-
lium bromide (MTT) assay) and cell death (B) (evaluated by lactate dehydrogenase
(LDH) release) in rat aortic smooth muscle cells (RASMCs) up to 4 h. Colorimetric
analysis of each value was normalized by arbitrarily setting the colorimetric value of
the non-stimulated control cells to 100% or 1. Each value represents the
mean ± standard deviation (S.D.; n ¼ 3) (*P < 0.05, compared with control. **P < 0.01,
compared with control).
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mechanical stretch-induced RASMC death
To further investigate the role of JNK and p38 activation in
stretch-induced RASMC death, we next examined the effects of JNK
and p38 inhibitors on stretch-induced RASMC death in comparison
with the effect of olmesartan. Fig. 5A compares the relative cell
viability of RASMCs after 4 h stretch with or without olmesartan, or
JNK and p38 inhibitors. It was found that olmesartan, the JNK in-
hibitor (SP600125), and the p38 inhibitor (SB203580) all signiﬁ-
cantly recovered the viability of the RASMCs. Fig. 5B compares the
LDH release from the RASMCs after 4 h stretch with or without
olmesartan, or JNK and p38 inhibitors. Compared with the positive
control, olmesartan, SP600125, and SB203580 signiﬁcantly reduced
the death rate of RASMCs after 4 h stretch. These results indicate
that olmesartan, and JNK and p38 inhibitors potentially inhibit
RASMC death induced by cyclic mechanical stretch.
4. Discussion
Hypertension is known as a primary risk factor for AAD, and
mechanical stretch is known to be one of the triggers for the onset
Fig. 4. Effects of different concentrations of olmesartan on the activation of c-Jun N-
terminal kinase (JNK) (A) and p38 (B) induced by cyclic mechanical stretch in rat aortic
smooth muscle cells (RASMCs). Olmesartan is abbreviated as Olm. Densitometric
analysis of each value was normalized by arbitrarily setting the densitometric value of
the control cells without stretch to 1. Each value represents the mean ± standard
deviation (S.D.; n ¼ 6). (*P < 0.05 compared with control without stretch, #P < 0.05
compared with 20 min stretch without olmesartan, ## P < 0.01 compared with stretch
20 min without olmesartan).
Fig. 5. Comparison of the cell viability (A) and lactate dehydrogenase (LDH) release (B)
induced by cyclic mechanical stretch in rat aortic smooth muscle cells (RASMCs) with
or without olmesartan or mitogen-activated protein (MAP) kinase inhibitors. Olme-
sartan, SP600125, and SB203580 are abbreviated as Olm, SP, and SB, respectively.
Colorimetric analysis of each value was normalized by arbitrarily setting of the
colorimetric value of the control (Ctrl.) cells without stretch to 100% or 1. Each value
represents the mean ± standard deviation (S.D.; n ¼ 11). (*P < 0.05 compared with
control without stretch, #P < 0.05 compared with stretch only).
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chanical stress transmitting signals to induce the onset of AAD is
poorly understood. In the present study, we investigated the in-
ﬂuence of acute mechanical stretch, which mimics an acute in-
crease in blood pressure, on the viability of aortic SMCs, which are
themain constituent cells of themedial layer of the aorta. As shown
in Fig. 1A, it was observed that acute cyclic mechanical stretch-
induced the death of RASMCs in a time-dependent manner, up to
4 h. These results are also supported by the ﬁndings that LDH
release from RASMCs was increased continually up to 4 h (Fig. 1B).
Taken together, it can be concluded that acute mechanical stretch
causes SMC death, which may be a possible cause of the onset of
AAD. Our ﬁndings are consistent with other reports that mechan-
ical stretch causes smooth muscle cell death (21,22). On the other
hand, some other researchers have reported that cyclic mechanical
stretch results in cell proliferation (23). We also observed such a
phenomenonwhenwe exposed RASMCs to 24 h of stretch (data not
shown). From these ﬁndings, we thought that cell death might
occur from the start of acute stretch stimulation up to 4 h after
which surviving cells entered a proliferation cycle, resulting in a
gradual increase in cell numbers that might be higher than that of
the initial control cell numbers at the end of 24 h. Therefore, it wassuggested that the extent and duration of mechanical stretch may
determine the cellular fate, such as death or proliferation. Our
experimental ﬁndings show that acute mechanical stretch for 4 h
causes continuous RASMC death. These ﬁndings may imply that an
acute rise in blood pressure leads to the death of SMCs, a main
component of the aortic medial layer. However, further studies
using in vivo experimental conditions are required to elucidate
whether an acute rise in blood pressure directly causes SMC death.
Next, stretch-induced changes in the intracellular signaling of
RASMCs were examined. It was reported that a high level of
phosphorylated JNK was observed in AAD tissues, and that
degeneration and tear of the aortic media had occurred in the AAD
lesion. (2,13). In addition, it was reported that inhibition of the
phosphorylation of JNK lead to regression of AAD (23). In the pre-
sent study, we found that acute mechanical stretch causes rapid
phosphorylation of JNK and p38 (Fig. 3A and B), which may lead to
SMC death. In fact, we also observed that SP600125, a JNK inhibitor,
and SB203580, a p38 inhibitor, both recovered stretch-induced
RASMC death evaluated based on the MTT reduction and LDH
release from the cells (Fig. 5A and B). Although we also found that
ERK1/2 are phosphorylated by mechanical stretch, ERK inhibitors
failed to inhibit stretch-induced RASMC death (data not shown).
Taking these observations together, mechanical stretch causes
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that may ultimately lead to the onset of AAD. On the other hand, a
previous study showed that angiotensin II acted as an agonist for a
potent inducer of AAD (1). In contrast to these ﬁndings, mechanical
stretch itself, which is independent of angiotensin II stimulation,
phosphorylated JNK and p38, and induced SMC death in our ex-
periments. Although we did not measure the amount of angio-
tensin II in the medium, angiotensin II itself is not likely involved in
JNK and p38 phosphorylation because stretch-induced AT1 recep-
tor activation was also observed in mesenteric and renal arteries
from angiotensinogen-knockout mice (24). Therefore, it is
conceivable that not only agonist stimulation, but also mechanical
stretch could have an important role in triggering the occurrence of
AAD.
ARBs are used all over the world for the treatment of patients
with hypertension (25). Olmesartan, one of the ARBs, is known as
an inverse agonist, which inhibits basic and stretch-induced acti-
vation of the AT1 receptor (17,26). In our present study, we found
that olmesartan inhibited phosphorylation of JNK and p38 (Fig. 4A
and B), and SMC cell death (Fig. 2) induced by acute mechanical
stretch. These results suggest that olmesartan inhibits stretch-
induced SMC death by suppression of phosphorylation of JNK and
p38. Therefore, it is assumed that inhibition of phosphorylation of
JNK and p38 by each inhibitor causes a reduction of stretch-induced
SMC death. This notion is supported by the ﬁndings that SP600125
and SB203580, as well as olmesartan, all recovered stretch-induced
RASMC death (Fig. 5A and B). We previously reported that azelni-
dipine, a calcium channel blocker, also inhibits stretch-induced
RASMC death (21). Since azelnidipine also inhibited stretch-
induced JNK, p38 phosphorylation, and SMC cell death, suppres-
sion of phosphorylation of JNK and p38 would be important in the
inhibition of SMC death induced by acute mechanical stretch (21).
Consistent with our results, it was reported that stretch-induced
cardiac hypertrophy was inhibited by candesartan, another
known inverse agonist of the AT1 receptor (17). Therefore, further
studies should be performed using ARBs other than olmesartan to
compare their various effects on stretch-induced RASMC death.
In the present study, we found that olmesartan inhibited acute
mechanical stretch-induced RASMC death through the inhibition of
JNK and p38 phosphorylation. Although future studies using in vivo
animal models are required to conﬁrm whether olmesartan also
inhibits the onset of AAD without affecting the blood pressure, our
present study may shed light on the development of a new phar-
macotherapy for the prevention of AAD.
5. Conclusion
In this study, we found that acute mechanical stretch causes JNK
and p38 phosphorylation, resulting in the death of cultured
RASMCs. It was suggested that olmesartan inhibited stretch-
induced RASMC death through the inhibition of JNK and p38-
mediated intracellular signaling pathways. Olmesartan is a poten-
tial candidate for the prevention of AAD, independent of its blood
pressure-lowering effect. Our ﬁndings may provide new insights
into alternative pharmacotherapy for patients with acute AAD.
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